Cochlear Ranked No. 1 Healthcare Company in Newsweek Trust Ranking for 2026

Cochlear has been ranked No. 1 in the Health Care & Life Sciences industry in Newsweek's World's Most Trustworthy Companies 2026, the second time in three years it has taken the top spot in the category. The hearing implant maker announced the ranking on October 14, 2026, according to PR Newswire.

How Newsweek and Statista Built the 2026 Ranking

Newsweek conducted the ranking independently with the global data research firm Statista, evaluating companies on the trust they inspire among customers, investors and employees. The 2026 edition is based on approximately 200,000 company evaluations from more than 65,000 participants across 20 countries, alongside an analysis of over 320,000 media mentions. Statista has run comparable trust and performance studies with other publishers, including a 2026 ranking of 500 health technology companies with TIME that weighted financial performance at 50%, reputation at 30% and online engagement at 20%, as Time reported on September 16, 2026.

Dig Howitt, Chief Executive Officer and President of Cochlear, said: "At Cochlear, our recipients and candidates are at the heart of everything we do. This recognition from Newsweek reflects the dedication of every person across our organization who works tirelessly to support people with hearing loss throughout their entire hearing journey." Cochlear was founded after Professor Graeme Clark set out to create the first multi-channel cochlear implant, and the company says it has helped more than 800,000 people of all ages in more than 180 countries hear since 1981.

Cochlear's Recent Expansion Moves

Cochlear launched its Nucleus Nexa System in India in March 2026, targeting an estimated 63 million people with hearing impairment, including over 100,000 babies born annually with hearing deficiency, according to akta.pro company records. In January 2026 the company expanded Nucleus Nexa System availability to eligible US military veterans at VA clinics nationwide, addressing hearing loss described as the most common war injury affecting three in five veterans. The same records show more than 750,000 implantable hearing devices delivered worldwide since 1981 and more than 650,000 registered Cochlear Nucleus Implants worldwide as of 2026.

Cochlear's Trial Recruitment and FY26 Results

Cochlear completed recruitment for its worldwide pivotal trial program evaluating fully implantable hearing technology, with over 100 patients implanted across the program, FinancialContent Business Page reported in September 2026. In August 2026, Investing.com reported that Cochlear's fiscal 2026 results showed a 2% increase in constant currency sales revenue to $2.3 billion, while underlying net profit declined 22% to $322 million. AInvest reported the same month that Cochlear's fiscal year underlying profit of A$322.4 million exceeded analyst estimates of A$296.4 million.

What Comes Next for Cochlear

Cochlear has not stated a date for the next edition of the Newsweek ranking. The company's pivotal trial program for fully implantable hearing technology has completed recruitment, with over 100 patients implanted across the program.